Updated Jul 16, 2026
Chadwick Jeremy G has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $15.60M.
Chadwick Jeremy G is a corporate executive associated with Kymera Therapeutics, Inc., a biotechnology company focused on drug discovery and development. He has been involved in various capacities within the company, contributing to its strategic direction and operational execution.
| Role | Insider |
|---|---|
| Notability | 75/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 600 | $82.08 | $49K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 3.7K | $81.50 | $300K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 551 | $80.71 | $44K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 4.5K | $80.02 | $360K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 3.8K | $79.39 | $302K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 324 | $79.17 | $26K |
| 2026-05-27 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 3.7K | $78.36 | $292K |
| 2026-04-24 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 300 | $90.00 | $27K |
| 2026-04-24 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise | 200 | $43.50 | $9K |
| 2026-04-24 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise | 100 | $30.17 | $3K |
| 2026-04-16 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 1.3K | $90.00 | $117K |
| 2026-04-16 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise | 1.3K | $43.50 | $57K |
| 2026-04-16 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 5.3K | $90.00 | $473K |
| 2026-04-16 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise | 785 | $43.50 | $34K |
| 2026-04-16 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise | 4.5K | $30.17 | $135K |
| 2026-04-01 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.1K | $86.05 | $95K |
| 2026-04-01 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale [10b5-1] | 13.5K | $85.41 | $1.16M |
| 2026-04-01 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise [10b5-1] | 14.6K | $29.64 | $434K |
| 2026-04-01 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale [10b5-1] | 7.6K | $85.38 | $649K |
| 2026-04-01 | KYMR | Kymera Therapeutics, Inc. | M — Option exercise [10b5-1] | 7.6K | $29.64 | $225K |
Chadwick Jeremy G is a corporate executive associated with Kymera Therapeutics, Inc., a biotechnology company focused on drug discovery and development. He has been involved in various capacities within the company, contributing to its strategic direction and operational execution.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 29 open-market sales ($15.60M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chadwick Jeremy G profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.